After promoting pump.fun for two days, the crypto account kimchi removed its profile reference to the platform. During the same period, pump.fun's revenue fell 16% from $1.61 million to $1.35 million, and active addresses dropped 11% from 178,539 to 159,492. While these changes occurred simultaneously, there is no clear evidence that the promotion caused the declines. Additionally, kimchi's wallet recently received 1.35 billion PUMP tokens worth about $6.25 million, matching a previous withdrawal of the same amount.
The story about kimchi removing its pump.fun reference comes with this market context from Pluang. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 24, 2026 02:31 WIB: Out of 50 major cryptocurrencies priced on Pluang, 36 rose and 13 fell today. Notable movers include ATOM (Cosmos) at Rp31.613 with a 1-day change of +2.92%, YFI (Yearn) at Rp39.776.295 with +2.84%, and LUNC (Terra Classic) at Rp0,832 with +2.50%.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
